The most common question patients ask us before a consultation is not about cost or logistics. It is: “How does ketamine actually work?” It is a good question, and one that conventional medicine left unanswered for too long.
At our clinic in Marietta, Georgia, we believe that understanding the neuroscience behind your ketamine treatments and therapies is part of informed decision-making. Ketamine has long been used as an anesthetic, and its rapid antidepressant effects have reshaped research into depression and glutamate-based treatments (Berman et al., 2000; Zanos & Gould, 2018).
A Different Target: Why Ketamine Works When Antidepressants Do Not
To explain ketamine, we first need to understand why conventional antidepressants can fall short for some patients. SSRIs, or selective serotonin reuptake inhibitors, and SNRIs, or serotonin-norepinephrine reuptake inhibitors, primarily affect monoamine neurotransmitters such as serotonin and norepinephrine. These medications help many people, but their full effects may take weeks to develop, and some patients do not achieve adequate relief after multiple medication trials (National Institute of Mental Health [NIMH], 2024).
Ketamine works through a different target: the glutamatergic system. Glutamate is the brain’s primary excitatory neurotransmitter. NMDA receptors, or N-methyl-D-aspartate receptors, are one type of glutamate receptor involved in synaptic signaling and neuroplasticity. In depression and chronic stress, research has linked disrupted glutamatergic signaling and synaptic changes in regions including the prefrontal cortex and hippocampus (Duman & Aghajanian, 2012; Zanos & Gould, 2018).
For patients exploring options after standard treatments have not provided adequate relief, understanding how ketamine clinics are revolutionizing depression treatment in GA can be an important part of the conversation.
NMDA Receptor Antagonism: What Blocking Does
Ketamine acts as an NMDA receptor antagonist. When administered intravenously, it temporarily reduces NMDA receptor activity. This triggers a downstream cascade involving other glutamate receptors, including AMPA receptors.
Researchers have proposed that increased AMPA receptor signaling after NMDA receptor blockade may contribute to cellular pathways associated with BDNF release and synaptic plasticity (Zanos & Gould, 2018).
One way we explain this process is to think of NMDA receptors as part of a braking system within a key neural communication pathway. When ketamine temporarily reduces that braking effect, other signaling pathways may become more active, supporting changes associated with neuroplasticity.
BDNF: The Brain’s Repair Protein
BDNF, or brain-derived neurotrophic factor, is one of the most studied proteins in neuroscience. It belongs to a family of molecules called neurotrophins, which support the survival, growth, and maintenance of neurons and their synaptic connections.
In plain terms, BDNF is often described as the brain’s fertilizer. It supports the growth and maintenance of synaptic connections that help neural circuits function effectively.
Chronic stress and depression have been associated with reduced BDNF signaling and synaptic changes in brain regions involved in mood and memory (Duman & Aghajanian, 2012). Preclinical research has also found that ketamine can rapidly increase synaptic signaling proteins and dendritic spine formation, which are structural features involved in synaptic communication (Li et al., 2010).
This research helps explain why ketamine has drawn attention for its speed. Clinical studies have reported antidepressant effects within hours to days for some participants, although response timing and durability vary by person (Berman et al., 2000; NIMH, 2024). You can also review our guide to how quickly ketamine may work for anxiety for a practical discussion of treatment timelines.
The HPA Axis: A Stress Connection
There is a second area of research worth understanding. The hypothalamic-pituitary-adrenal, or HPA, axis is the body’s primary stress-response system. Chronic stress can disrupt HPA-axis activity and contribute to changes in cortisol, glutamate signaling, and synaptic health.
Research suggests ketamine may influence stress-related glutamate activity and neuroplasticity pathways, though the precise contribution of these effects to each person’s outcome remains under study (Duman & Aghajanian, 2012; Zanos & Gould, 2018).
This may help explain why some patients experience benefits beyond the immediate treatment session, particularly when care is approached as part of an individualized treatment plan rather than as a single intervention.
The Synaptogenic Hypothesis
The unifying framework for these mechanisms is often called the synaptogenic hypothesis of antidepressant action. This model proposes that depression may involve synaptic dysfunction or loss, and that treatments supporting synaptic recovery may play an important role in symptom improvement (Duman & Aghajanian, 2012).
Ketamine is one of the best-studied examples of rapid synaptic changes in preclinical research. It is not simply another antidepressant with a slightly different formula. Its glutamate-based mechanism represents a meaningful departure from medications that primarily target monoamine neurotransmitters.
SPRAVATO®: A Related Mechanism
SPRAVATO®, also known as esketamine, is the S-enantiomer of ketamine and an NMDA receptor antagonist. It is FDA-approved for treatment-resistant depression in adults, either as monotherapy or with an oral antidepressant. It is also approved for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior when used with an oral antidepressant (U.S. Food and Drug Administration [FDA], 2025).
SPRAVATO® is administered as a nasal spray under healthcare-provider supervision through a restricted REMS program, with observation for at least two hours after administration (FDA, 2025). We offer SPRAVATO® at our Marietta clinic for qualifying patients and can discuss coverage questions during a consultation. For a detailed comparison of your options, see our overview of SPRAVATO® vs. ketamine therapy: which is right for you.
IV ketamine infusion therapy for psychiatric conditions is an off-label use. Ketamine itself is not FDA-approved to treat psychiatric disorders (FDA, 2022).
What Matters for Your Treatment Decision
Understanding this neuroscience matters for practical reasons. When patients know that ketamine works through glutamate signaling and neuroplasticity pathways rather than simply altering monoamine levels, several things become clearer:
- Why some responses can appear more quickly than with standard antidepressants.
- Why a clinician may recommend an individualized treatment series rather than a single session.
- Why ketamine may be considered after standard treatments have not provided adequate relief.
- Why outcomes vary from person to person.
No biological explanation can predict an individual result. We encourage every patient to discuss what this mechanism may mean for their specific clinical situation, medical history, and realistic treatment goals.
Frequently Asked Questions
Why does ketamine work so much faster than SSRIs?
SSRIs can take several weeks to reach their full effect. Ketamine works through a different biological mechanism, and studies have found antidepressant effects within hours to days for some participants. Individual response and timing vary (Berman et al., 2000; NIMH, 2024).
Is ketamine addictive?
Ketamine has misuse potential, particularly outside of medical care. At our clinic, treatment begins with medical screening and is delivered in a monitored setting. We encourage patients with a personal or family history of substance use concerns to discuss those factors openly during intake. Ketamine’s potential for misuse is an important consideration in treatment planning (NIMH, 2024).
What is the difference between the glutamatergic system and the serotonin system?
Serotonin is a monoamine neurotransmitter involved in mood regulation. Glutamate is the brain’s primary excitatory neurotransmitter and is involved in learning, memory, and synaptic communication. Ketamine targets the glutamatergic system through NMDA receptors, while SSRIs target serotonin reuptake (Zanos & Gould, 2018).
Does BDNF from ketamine permanently repair the brain?
We do not describe BDNF-related changes as a permanent repair. Preclinical studies suggest ketamine can produce rapid synaptic changes, but the durability of clinical benefit varies by individual and may depend on many factors, including diagnosis, treatment plan, and ongoing care (Li et al., 2010; Zanos & Gould, 2018).
How do I know if I am a candidate for IV ketamine at our clinic?
Candidacy begins with a comprehensive medical and psychiatric evaluation. We consider your history, current symptoms, medications, treatment experience, and safety considerations before making recommendations. You can learn what to look for in a ketamine clinic before scheduling your first visit.
Key Takeaways
- Ketamine is an NMDA receptor antagonist that targets the glutamatergic system rather than the monoamine system targeted by SSRIs and SNRIs (Zanos & Gould, 2018).
- NMDA receptor blockade is associated with downstream AMPA signaling and neuroplasticity pathways involving BDNF (Zanos & Gould, 2018).
- Clinical studies have reported rapid antidepressant effects for some patients, sometimes within hours to days, though individual results vary (Berman et al., 2000; NIMH, 2024).
- Chronic stress, HPA-axis dysregulation, and synaptic changes are part of the broader research context for depression and neuroplasticity (Duman & Aghajanian, 2012).
- SPRAVATO® is FDA-approved for specific depressive-disorder indications, while IV ketamine for psychiatric conditions is used off-label (FDA, 2022, 2025).
If you have been searching for a clear explanation of what ketamine therapy actually does and whether it might help you, we hope this gives you a solid foundation. At our clinic in Marietta, we are committed to making sure every patient understands their treatment before they begin. Call us at 770-580-1042 or schedule a consultation with our team.
References
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000). Antidepressant effects of ketamine in depressed patients. Biological Psychiatry, 47(4), 351–354. DOI: https://doi.org/10.1016/S0006-3223(99)00230-9
Duman, R. S., & Aghajanian, G. K. (2012). Synaptic dysfunction in depression: Potential therapeutic targets. Science, 338(6103), 68–72. DOI: https://doi.org/10.1126/science.1222939
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science, 329(5994), 959–964. DOI: 10.1126/science.1190287
National Institute of Mental Health. (2024, October 24). New hope for rapid-acting depression treatment. National Institutes of Health.
U.S. Food and Drug Administration. (2025, January). SPRAVATO® (esketamine) nasal spray: Prescribing information.
Zanos, P., & Gould, T. D. (2018). Mechanisms of ketamine action as an antidepressant. Molecular Psychiatry, 23(4), 801–811. DOI: 10.1038/mp.2017.255
Medical Disclaimer
The information in this blog is for educational purposes only and does not constitute medical advice. Treatment for PTSD, depression, anxiety, and trauma-related conditions, including IV ketamine infusion therapy and SPRAVATO®, should only be pursued under the supervision of a licensed provider familiar with your full medical and psychiatric history. Individual results vary. SPRAVATO® is FDA-approved for specific indications; IV ketamine for psychiatric conditions is used off-label. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide & Crisis Lifeline or go to your nearest emergency room.
